Acurx Pharmaceuticals Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
4
- Stock Symbol
-
ACXP
- Share Price
-
$0.96
- (As of Friday Closing)
Acurx Pharmaceuticals General Information
Description
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Contact Information
Website
www.acurxpharma.comCorporate Office
- 259 Liberty Avenue
- Staten Island, NY 10305
- United States
Corporate Office
- 259 Liberty Avenue
- Staten Island, NY 10305
- United States
Acurx Pharmaceuticals Timeline
Acurx Pharmaceuticals Stock Performance
As of 13-Nov-2026, Acurx Pharmaceuticals’s stock price is $0.96. Its current market cap is $5.82M with 6.06M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.96 | $0.98 | $0.92 - $7.54 | $5.82M | 6.06M | 124K | -$2.67 |
Acurx Pharmaceuticals Financials Summary
As of 30-Jun-2026, Acurx Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (2,593) | (60) | 7,988 | 45,679 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (7,669) | (8,092) | (14,123) | (14,578) |
| Net Income | (7,506) | (7,967) | (14,103) | (14,578) |
| Total Assets | 10,985 | 7,690 | 3,858 | 7,709 |
| Total Debt | 0 | 0 | 0 |
Acurx Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Acurx Pharmaceuticals Comparisons
Industry
Financing
Details
Acurx Pharmaceuticals Competitors (6)
One of Acurx Pharmaceuticals’s 6 competitors is Verrica Pharmaceuticals, a Formerly VC-backed company based in West Chester, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Verrica Pharmaceuticals | Formerly VC-backed | West Chester, PA | ||||
| AffyMax | Formerly VC-backed | New York, NY | ||||
| Arcutis Biotherapeutics | Formerly VC-backed | Westlake Village, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Dendreon | Formerly VC-backed | Seal Beach, CA |
Acurx Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Acurx Pharmaceuticals Patents
Acurx Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026060121-A1 | Inhibitors of dna polymerase iiic in gram-positive bacteria, pharmaceutical compositions thereof, and uses thereof | Pending | 13-Sep-2024 | ||
| AU-2023365685-A1 | Compounds and methods for improving health | Pending | 17-Oct-2022 | ||
| EP-4587028-A2 | Compounds and methods for improving health | Pending | 17-Oct-2022 | ||
| EP-4587028-A4 | Compounds and methods for improving health | Pending | 17-Oct-2022 | ||
| US-20260144796-A1 | Compounds and methods for improving health | Pending | 17-Oct-2022 | A61K31/5377 |
Acurx Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Acurx Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Acurx Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Acurx Pharmaceuticals FAQs
-
When was Acurx Pharmaceuticals founded?
Acurx Pharmaceuticals was founded in 2017.
-
Where is Acurx Pharmaceuticals headquartered?
Acurx Pharmaceuticals is headquartered in Staten Island, NY.
-
What is the size of Acurx Pharmaceuticals?
Acurx Pharmaceuticals has 4 total employees.
-
What industry is Acurx Pharmaceuticals in?
Acurx Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Acurx Pharmaceuticals a private or public company?
Acurx Pharmaceuticals is a Public company.
-
What is Acurx Pharmaceuticals’s stock symbol?
The ticker symbol for Acurx Pharmaceuticals is ACXP.
-
What is the current stock price of Acurx Pharmaceuticals?
As of 13-Nov-2026 the stock price of Acurx Pharmaceuticals is $0.96.
-
What is the current market cap of Acurx Pharmaceuticals?
The current market capitalization of Acurx Pharmaceuticals is $5.82M.
-
Who are Acurx Pharmaceuticals’s competitors?
Verrica Pharmaceuticals, AffyMax, Arcutis Biotherapeutics, Kite Pharma, and Dendreon are some of the 6 competitors of Acurx Pharmaceuticals.
-
What is Acurx Pharmaceuticals’s annual earnings per share (EPS)?
Acurx Pharmaceuticals’s EPS for 12 months was -$2.67.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
